| abstract |
The present invention provides compounds effective as modulators of sphingosine-1-phosphate receptors for the treatment of cardiopulmonary diseases such as hypertension (including malignant hypertension), angina, myocardial infarction, arrhythmia , congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, rhythm disorders, cardiomyopathy (including hypertensive cardiomyopathy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis , Croup, Emphysema, Pleurisy, Pulmonary Fibrosis, Pneumonia, Pulmonary Embolism, Pulmonary Hypertension, Mesothelioma, Ventricular Conduction Abnormalities, Complete Heart Obstruction, Adult Respiratory Distress Syndrome, Sepsis Syndrome, Idiopathic Pulmonary Fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation or cirrhosis. |